Biotherapeutics Market Report

Furthermore, the US with USD 94 billion market in 2024, held a largest share in the global biotherapeutics market. 

• Johnson & Johnson (US) gets European Commission approval for its monoclonal antibody IMAAVY® (nipocalimab) as the first FcRn blocker for adults and adolescents with generalized myasthenia gravis. Nipocalimab provided superior symptom improvement versus standard therapy and demonstrated a favorable safety profile. This marked a major advance in long-term management of antibody-positive gMG patients. (December 02, 2025)
• Johnson & Johnson (US) get FDA approval for DARZALEX FASPRO® as the first single-agent treatment for adults with high-risk smoldering multiple myeloma (HR-SMM). The Phase 3 AQUILA trial showed 51% reduction in progression risk to active multiple myeloma vs. active monitoring, with 63.1% progression-free at 5 years. (November 6, 2025)
• Novartis (Switzerland) agreed to acquire Avidity Biosciences for USD 12 billion to strengthen its RNA therapeutics and neuromuscular disease pipeline. The deal added Avidity’s late-stage Antibody Oligonucleotide Conjugate (AOC™) platform, including programs for DM1, FSHD, and DMD. (October 26, 2025)

Drivers: Rising Prevalence of Chronic Diseases

More people around the world are suffering from serious long-term diseases like cancer, diabetes, autoimmune disorders, and heart conditions, which is the biggest reason the biotherapeutics market is growing so fast. In the United States, cancer alone causes nearly 618,000 deaths every year according to NIH data, creating a strong push for advanced treatments such as monoclonal antibodies that make up the largest share of this market. These biologics work by precisely targeting disease cells, offering better results than older chemical drugs with fewer side effects. Companies like Eli Lilly are cashing in big time—their Mounjaro drug for diabetes saw sales jump 114% year-over-year in early 2024, showing how effective these therapies are for managing chronic illnesses. As populations age and lifestyles lead to more obesity and pollution-related health issues, demand keeps rising globally, especially in North America and Europe where healthcare spending is high. This patient need drives biopharma firms to invest heavily in R&D, ensuring steady market expansion through new approvals and expanded uses for existing drugs.

Opportunities: Development of Biosimilars and Emerging Markets

A huge chance lies in biosimilars—affordable versions of blockbuster biologics once their patents expire—which will flood the market with cheaper options and help millions more patients get life-saving treatments. With drugs like Humira’s patents ending, companies in India and China are ramping up production, cutting costs by 30-50% while matching the originals’ quality. Governments are helping too: China’s NMPA fast-tracked GSK’s Shingrix vaccine, and India’s DCGI is easing biosimilar approvals to boost exports. This opens massive new markets in Asia-Pacific, where chronic diseases are exploding but high prices block access. For big players, it means licensing deals and partnerships with local manufacturers, while startups can focus on next-gen therapies like cell/gene treatments. Overall, biosimilars could save healthcare systems $100B+ by 2030, sparking competition that lowers prices and speeds adoption in emerging economies without halting original drug innovation

Challenges: High Manufacturing Costs and Regulatory Complexity

Producing biotherapeutics is extremely costly and technically difficult because it requires living cells in special cleanroom factories called bioreactors, plus years of testing to meet tough safety rules from agencies like the FDA and EMA. Capacity shortages are a constant headache—Novo Nordisk alone poured over $19 billion (DKK 129 billion) into new plants and acquisitions in 2024 just to keep up with demand for their insulin and obesity drugs. Even when drugs get fast-tracked for approval, there’s big risk: if later studies don’t confirm benefits, the FDA can pull them off the market, as happened with Makena in 2023 after nearly a decade. This uncertainty scares investors, jacks up prices for patients (often $10,000+ per dose), and causes supply chain delays from raw material issues like single-use plastics or cell media. Skilled workers are also hard to find, and any contamination can ruin entire batches worth millions. These hurdles slow innovation and make it tough for smaller biotechs to compete with giants.

The global biotherapeutics market, a critical component of modern healthcare, represents a significant and essential segment focused on the development and production of biologically derived therapies like monoclonal antibodies, recombinant proteins, vaccines, and cell/gene treatments. Valued at USD 294 billion in 2024, the biotherapeutics market is projected to reach USD 477 billion by 2030, reflecting a CAGR of 8.4 % during the forecast period. This expansion is driven by rising chronic diseases like cancer and autoimmune disorders, surging demand for precision biologics, and advancements in oncology/immunology applications. Innovations include continuous bioreactors for higher yields, AI-optimized cell line development, and single-use systems reducing contamination in complex manufacturing.